Company Announcements
The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. announced that its biologics license application for HLX11, a biosimilar to Perjeta® (pertuzumab), has been accepted by the U.S. FDA. The acceptance positions the company to expand its market reach in the U.S. for treatments of HER2-positive breast cancer. This development follows successful phase 3 clinical trials and a global commercialization agreement with Organon, underscoring the company’s strategic growth in the oncology sector.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in the People’s Republic of China, focused on the development and commercialization of biosimilars. The company specializes in biologics, with a market focus on treatments for various types of cancer, including breast cancer.
YTD Price Performance: -29.28%
Average Trading Volume: 675,461
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$9.11B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
